Since its creation sixteen years ago the Society of Biomolecular Sciences has worked to promote its vision of advancing the science of drug discovery through holding a series of quality scientific symposia across North America and Europe. These symposia have provided a meeting place between scientists interested in pre- candidate drug discovery from the pharmaceutical, biotechnology and academic sectors to hear cutting-edge science from industry leading speakers, to network and share knowledge around the technologies applied to pre-candidate drug discovery and to meet with members of the vendor community at the vendor exhibitions that are a major component of all SBS meetings.

In recent years, there has been significant growth within the drug-discovery community in China and elsewhere in Asia. Starting with the growth of the CRO sector, many pharmaceutical companies have now established research and development centers in China and there is an emerging and vibrant academic and biotechnology community elsewhere in Asia. This conference, the first of a planned series of annual meetings of SBS in China, will bring to China the traditional strengths of SBS as a forum for sharing best practices in drug discovery.

With leading speakers from China and elsewhere, this symposium will explore the state of the art of small molecule drug discovery focusing on the challenges and recent advances associated with assay development, compound management and compound screening. Other sessions will explore the two most tractable target classes—enzymes and G-protein coupled receptors—and will include a series of presentations highlighting successful drug discovery organizations within China and elsewhere in Asia.

This conference will offer a unique opportunity to meet leaders in the field from Europe, North America and China. The meeting will be complemented by a vendor exhibition which will provide opportunities for attendees to learn about advances in the application of novel drug discovery technologies.

On behalf of SBS and the organizing committee, we would like to invite you to join us in Shanghai on the 7th through 9th December at the launch of SBS in China.

Speakers

The following speakers will be presenting （as of June 15, 2010）:

Robert Campbell, Ph.D., Eli Lilly and Company
Taosheng Chen, Ph.D., St. Jude Children's Research Hospital
Mei Cong, Ph.D., Promega Corporation
Richard Eglen, Ph.D., PerkinElmer
William Janzen, University of North Carolina at Chapel Hill
Christopher J. Langmead, Ph.D., Heptares Therapeutics
Ge Li, Ph.D., WuXi AppTec
Rob Lifely, Ph.D., GlaxoSmithKline
Christopher A. Lipinski, Ph.D., Melior Discovery
John Mathias, Ph.D., Pfizer
Lorenz M. Mayr, Ph.D., Novartis Institutes for BioMedical Research （NIBR）
Graeme Milligan Ph.D., FRSE, University of Glasgow
Seymour Mong, Ph.D., Jiangsu Hengrui Medicine Company
Jeff Paslay, Ph.D., Pfizer
Kevin Pfleger, Ph.D., University of Western Australia
Stephen Rees, GlaxoSmithKline
Melvin Reichman, Ph.D., Lankenau Institute for Medical Research
      Chemical Genomics Center
Sitta Sittampalam, Ph.D., University of Kansas Medical Center
Michael Xie, Ph.D., GlaxoSmithKline
Steve Yang, Ph.D., Pfizer
Wei Zheng, Ph.D., National Institutes of Health
Lance Laing, Ph.D.
Kiaxian Chen, Ph.D., Shanghai Institute of Materia Medica （SIMM）
En Li, Ph.D., Novartis

Attendee Rates